Skip to main content
Terug
Watch Compare

Cellectar Biosciences, Inc.

Datakwaliteit: 83%
CLRB
NASDAQ Manufacturing Chemicals
€ 2,95
▲ € 0,21 (7,66%)
6 months return
—
Momentum
Neutral
ROE
-309,48%

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-309,48%
Onder sectorgemiddelde (-54,49%)
ROIC-206,96%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio2,77
Interest CoverageN/A

Waardering

PE (TTM|NTM)
-0,55 | -0,89
Boven sectorgemiddelde (-1,50)
P/B Ratio1,50
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -23,12 M

Price History

Financiële Trends

Koersdoel Analisten

3 analisten
Buy
+1029.9%
upside to target
Huidig
€ 2,95
Consensus Target
€ 33,33
€ 10,00
Laag
€ 76,00
Hoog
Vooruitzicht
Forward K/W
-0,89
Forward WPA
-€ 3,10
Omzet Sch.
11,48 M

Winstverassingen

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -€ 1,89 · Rev Est: 0,0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -€ 4,20 -€ 3,39 -€ 1,41 -€ 0,53 — —
Estimate -€ 4,90 -€ 3,70 -€ 2,53 -€ 1,23 -€ 1,89 -€ 1,05
Verrassing +14,29% +8,38% +44,21% +56,73% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -309,48% · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -21,79 M
ROE -309,48% ROA -153,88%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -23,12 M
ROIC -206,96% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 2,77
Debt / Equity N/A Current Ratio 2,77
Interest Coverage N/A Asset Turnover N/A
Working Capital 8,71 M Tangible Book Value 8,00 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -0,55 · EV/EBITDA: N/A
P/E Ratio -0,55 Forward P/E -0,89
P/B Ratio 1,50 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 1,05 Fwd Earnings Yield N/A
FCF Yield -192,71%
Market Cap 12,00 M Enterprise Value -554.710,0

Per Share

EPS: -8,35 · FCF/Share: -5,45
EPS (Diluted TTM) -8,35 Revenue / Share N/A
FCF / Share -5,45 OCF / Share -5,45
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 106,12% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 106,12%
SBC-Adj. FCF -26,35 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -21,79 M -44,58 M -37,98 M -28,60 M -24,12 M
EPS (Diluted) -8,35 -1,40 -3,11 -4,05 -0,76
Gross Profit — — — — —
Operating Income -22,98 M -51,78 M -38,96 M -28,81 M -24,13 M
EBITDA — — — — —
R&D Expenses 11,50 M 26,14 M 28,21 M 19,22 M 17,59 M
SG&A Expenses — — — — —
D&A 213.597,0 291.653,0 192.375,0 148.435,0 —
Interest Expense — — — — —
Income Tax 66.000,0 66.000,0 -60.000,0 -60.000,0 —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 14,98 M 25,47 M 12,08 M 21,59 M 37,20 M
Total Liabilities 5,06 M 9,80 M 13,43 M 6,08 M 4,16 M
Shareholders' Equity 8,54 M 14,29 M -1,36 M 15,51 M 33,05 M
Total Debt — — — — —
Cash & Equivalents 13,20 M 23,29 M 9,56 M 19,87 M 35,70 M
Current Assets 14,04 M 24,25 M 10,45 M 20,53 M 36,57 M
Current Liabilities 4,75 M 9,39 M 12,94 M 5,53 M 3,99 M

Sectorvergelijking

vs Manufacturing sector mediaan (1605 peers)
Metriek Aandeel Sector Mediaan
P/E -0,6 -1,5
P/B 1,5 1,6
ROE % -309,5 -54,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3